Trial: 202105011

A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

Phase

II

Principal Investigator

Huang, Frederick

Disease Site

Brain and Nervous System; Other Endocrine System

Learn more about this study at: clinicaltrials.gov